Executive Leadership

David has over thirty years of industry experience, where he held various global executive leadership positions in large pharmaceutical and commercial-stage biotechnology companies focused on oncology including as chief executive officer (CEO) of Ipsen, a leading global biopharmaceutical company.

During his tenure as CEO at Ipsen, David led the transformation of the company into a high-growth and leading global biopharmaceutical organization through the expansion of the oncology portfolio in the U.S. and Europe, and growing the R&D portfolio through internal and external innovation.

David most recently served as president, CEO and board member of FerGene focused on developing an innovative gene therapy for bladder cancer. His prior leadership roles include serving as executive vice president and president of oncology at Baxalta from 2014 to 2016, until its acquisition by Shire plc. He was also chief commercial officer of Endocyte from 2012 to 2014. Prior to that, Mr. Meek served in various executive leadership roles at Novartis Pharma and Novartis Oncology after beginning his career at Johnson & Johnson and Janssen from 1989 to 2004. He holds a Bachelor of Arts from the University of Cincinnati.  Prior to his biopharma career, David was an active duty commissioned officer in the U.S. Army achieving the rank of Captain.

David has also served on the boards of Entasis Therapeutics Holdings Inc., Pharmaceutical Research and Manufacturers of America (PhRMA) and European Federation of Pharmaceutical Industries and Associations (EFPIA), and currently serves on the board of uniQure N.V.

Chuck served as President and Chief Executive Officer of Mirati Therapeutics from 2012-2021. He is currently President, Founder and Head of Research and Development at Mirati, and is a Board Member.

Under his leadership, Mirati has transformed into a precision oncology company focused on advancing drug discovery and research and delivering novel therapeutics that target the genetic and immunologic drivers of cancer.

Prior to joining Mirati, Chuck was Senior Vice President for Biotherapeutic Clinical Research within Pfizer’s Worldwide Research & Development division. He was at Pfizer from 2003 to 2012, serving in roles of increasing responsibility, including Vice President, Head of Oncology Development and Chief Medical Officer for Pfizer’s Biotherapeutics and Bioinnovation Center. He was responsible for the development of Pfizer’s oncology portfolio, including Inlyta,* Xalkori* and the approval of Sutent.* Prior to Pfizer, Chuck was at Schering-Plough where he was responsible for the Phase I-IV development of several oncology compounds, including Temodar.*

Chuck’s career has also included academic and hospital positions at Stanford and Emory universities. He currently serves on the board of directors at PMV Pharmaceuticals, Inc., Odyssey Therapeutics and Poseida Therapeutics. Chuck is also on the Scientific Advisory Board at ALX Oncology. Previously, he served as a member of the board of Array Biopharma from 2014 to 2019 when it was acquired by Pfizer, Inc., Immunomedics from 2019 to 2020 when it was acquired by Gilead, and BCTG Acquisition Corp from 2020 to 2021 when it merged with Tango Therapeutics.

Chuck received his M.D. and Ph.D. degrees from Washington University School of Medicine and completed his post-graduate training at Stanford University. Additionally, he has received research support from the National Institutes of Health and the American Cancer Society, published more than 50 peer-reviewed manuscripts and holds a number of patents and patent applications.

* Trademarks are property of their respective owners.

Jamie joined Mirati in 2013 as Chief Scientific Officer. In his role, Jamie is responsible for drug discovery, translational research, drug manufacturing and companion diagnostics research. At Mirati, Jamie has led activities related to the discovery and advancement of the company’s clinical and preclinical programs, including adagrasib (KRAS G12C selective inhibitor), MRTX1133 (KRAS G12D selective inhibitor) and sitravatinib (spectrum-selective receptor tyrosine kinase (RTK) inhibitor).

Prior to Mirati, Jamie was the head of Oncology Precision Medicine and a member of the executive leadership team in the Oncology Research Unit at Pfizer. He joined Pfizer in 2003, and his responsibilities included leading oncology nonclinical research and translational sciences for programs including Sutent* and Xalkori.*

Prior to Pfizer, Jamie held positions at SUGEN/Pharmacia as a Group Leader on the Preclinical Research and Exploratory Development team. He began his industry experience at Warner Lambert/Parke-Davis.

Jamie has authored or co-authored over 140 peer-reviewed research articles in scientific journals including Science, Nature, Cancer Cell, Cancer Discovery, New England Journal of Medicine and many others. In addition, he also participates on the editorial boards for Cancer Research and Molecular Cancer Therapeutics and is a member of the Scientific Advisory panel at Bridge Bio/QED.

Jamie received his Ph.D. at North Carolina State University and his B.S. in biology from Northern Illinois University.

* Trademarks are property of their respective owners.

Ben joined Mirati in 2020 as Chief Commercial Officer, bringing with him almost 20 years of industry experience. Ben is responsible for building and leading commercial and medical affairs functions and capabilities as Mirati prepares for commercial readiness. Ben has a long track record of leading commercial teams, including global product launches for innovative oncology treatments. Prior to Mirati, Ben was Senior Vice President, Chief Commercial Officer at Halozyme Therapeutics, where he was responsible for the global commercial strategy for the company’s oncology portfolio.

Prior to Halozyme, Ben spent 17 years at Bristol Myers Squibb in various roles, including General Manager, UK & Ireland, where he oversaw an organization of more than 300 people, and Vice President Marketing, Immuno-Oncology, where he led the commercialization of Yervoy* and oversaw the launch preparedness of Opdivo* across more than eight indications. Ben currently serves as board director at Surface Oncology.

Ben received both his MBA and B.S. in Management from St. John’s University in Queens, New York.

* Trademarks are property of their respective owners.

John joined Mirati in 2023 as Chief Legal Officer and has more than 25 years of legal and business leadership across leading global biotech companies. Most recently, he was Executive Vice President and Chief Legal Officer at Olema Pharmaceuticals and helped build out the company and lead it through its successful Series C financing and 2020 Initial Public Offering.

Previously he was Executive Vice President and General Counsel for Portola Pharmaceuticals, Inc., where he was responsible for all legal, governance and compliance matters supporting the company’s products, its corporate strategy, and the build-out of its operations in the United States and Europe, which culminated in Portola’s acquisition by Alexion Pharmaceuticals, Inc. in July 2020. Prior to Portola, John was General Counsel of Alexion for more than five years during a period of tremendous growth and value creation. He was responsible for overseeing all global legal matters spanning 50 countries, as well as managing Alexion’s Global Government Affairs and Global Corporate Communications teams.

Earlier in his career, John was General Counsel at Elan Corporation plc and a senior lawyer at Amgen. John also worked as in the healthcare practice of a national law firm and was a healthcare fraud prosecutor in the U.S. Attorney’s Office and in the Virginia Attorney General’s Office. John earned his undergraduate degree from the University of Virginia and his law degree from the University of Georgia School of Law cum laude. From 2015 through 2022 John served on the Board of Trustees for the American Kidney Fund and chaired the Audit and Compliance Committee.

Mike joined Mirati in 2022 as Chief People Officer (CPO), bringing over 20 years of broad, global people leadership experience working with Boards of Directors and C-level executives to improve organizational capabilities. As CPO, Mike is responsible for guiding and growing Mirati’s people and capabilities, as well as focusing on the company’s talent advancement and growth.

Most recently, Mike served as executive vice president and chief human resources officer at Arena Pharmaceuticals (acquired by Pfizer). Prior to this, he held executive leadership positions at Halozyme Therapeutics, Inc., CareFusion, NuVasive and Life Technologies. Additionally, Mike spent time in leadership roles at Hewlett Packard and EDS (acquired by Hewlett Packard).

Mike currently serves on the board of directors for Orthofix Medical and Silvaco. He received his B.S. in Finance from The Ohio State University.

Alan joined Mirati in 2022 as Chief Medical Officer. In his role, Alan provides leadership and direction over clinical development and operations, regulatory affairs, drug safety and medical strategy. Alan brings nearly 30 years of oncology and drug development experience across industry and academia.

Prior to Mirati, Alan was the president, head of global development, oncology, at Zai Lab. Prior to joining Zai Lab, he was the SVP and global head of late-stage oncology at Genentech, a member of the Roche Group. During his tenure at Genentech/Roche, he led the teams responsible for the global development and regulatory approval of several innovative medicines, most recently Tecentriq^®. Prior to joining Genentech/Roche, Alan served as professor and chief of hematology/oncology at Oregon Health and Science University. Previously, he served on the faculties of the medical schools of Indiana University and Vanderbilt University.

Alan holds a Doctor of Medicine degree from Rush Medical College. He completed his training in internal medicine and a fellowship in medical oncology at Yale-New Haven Medical Center. He has over 300 publications, including articles, reviews, abstracts and book chapters.

Laurie joined Mirati in 2022 as Chief Financial Officer (CFO), bringing with her 25 years of experience in biopharmaceutical management. In her role at Mirati, Laurie is responsible for leading Finance and Accounting, Corporate Affairs, Facilities and Information Technology. Prior to Mirati, Laurie served as the Executive Vice President and CFO of Arena Pharmaceuticals (acquired by Pfizer). Prior to joining Arena, she was the CFO at Halozyme Therapeutics.

Earlier in her career, Laurie held senior management roles at Shire Plc, including Senior Vice President of Finance, Division CFO for the Regenerative Medicine Division, and Head of Investor Relations. Previously she held positions of increasing responsibility during her fifteen-year career at Amgen, Inc., spanning the areas of finance and international/emerging markets.

Laurie currently serves on the board of directors for Surface Oncology and PMV Pharmaceuticals, Inc. She received her B.S. in Accounting from Arizona State University, and her M.B.A. from the Anderson School of Management at the University of California, Los Angeles.